Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amphetamine-related Disorders Clear all
Completed Phase 1 Interventional

Safety Interaction Trial Ibudilast and Methamphetamine

NCT01217970
View directory record Official record
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Jul 23, 2026, 3:38 PM EDT
Withdrawn No phase listed Observational

Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates

NCT00865332
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

NCT04235686
View directory record Official record
Conditions
Bipolar Depression
Interventions
Mydayis Extended-Release Capsule, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Not listed Phase 1 Interventional

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

NCT00265278
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Modafinil
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

NCT04982796
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Psilocybin, Treatment-as-usual
Drug · Behavioral
Lead sponsor
Portland VA Research Foundation, Inc
Other
Eligibility
25 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Vancouver, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 23, 2026, 3:38 PM EDT
Not listed Phase 1 Interventional

Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

NCT00040040
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Not listed Phase 1 Interventional

Effects of Stimulant Dependence on Human Striatal Dopamine System - 15

NCT00000350
View directory record Official record
Conditions
Amphetamine-Related Disorders, Tobacco Use Disorder
Interventions
radioactive substance
Procedure
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jul 23, 2026, 3:38 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Lobeline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed No phase listed Observational

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00698737
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

NCT02144415
View directory record Official record
Conditions
Healthy Volunteers, Drug Users
Interventions
EB-1020 400 mg, EB-1020 800 mg, lisdexamfetamine 150 mg, d-amphetamine 40 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 3:38 PM EDT
Completed No phase listed Observational

Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals

NCT00429767
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Jul 23, 2026, 3:38 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

NCT05790239
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy
Drug · Behavioral
Lead sponsor
Stephen Robert Marder
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Tyrosine for Methamphetamine Dependence - 1

NCT00000322
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Tyrosine
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Terminated Phase 1 Interventional

Amphetamine Cocaine Interaction Study - 2

NCT00000305
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Dextroamphetamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Bupropion for the Treatment of Methamphetamine Dependence - 1

NCT00069251
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Costa Mesa, California • San Diego, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)

NCT01449565
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Jul 23, 2026, 3:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Hospital-Based Contingency Management

NCT05515757
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Mobile-app based contingency management
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 23, 2026, 3:38 PM EDT
Not listed Phase 1 Interventional

Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1

NCT00033072
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Selegiline
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence

NCT00377299
View directory record Official record
Conditions
Amphetamine Abuse, Amphetamine Dependence, Bipolar Disorder, Major Depressive Disorder
Interventions
Citicoline, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional

A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence

NCT01577797
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Text messages
Behavioral
Lead sponsor
New Leaf Treatment Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lafayette, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional

Ondansetron for the Treatment of Methamphetamine Dependence - 1

NCT00040053
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Ondansetron
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Chula Vista, California • Costa Mesa, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 3:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

NCT00553319
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder, Cocaine Dependence
Interventions
Placebo, Adderall-XR
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 23, 2026, 3:38 PM EDT